Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for COVID-19
NCT05741099Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Medical University. Primary endpoint: Effectiveness evaluation at 1 year. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05741099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741099.